TSO3 IncTSX: TOS

Canaccord Genuity Updates Coverage on TSO3 Inc. - Video Posted on InvestmentPitch.com

· Issued by TSO3 Inc via Newsfile

Vancouver, British Columbia--(Newsfile Corp. - May 14, 2013) - Canaccord Genuity has updated coverage on TSO3 Inc. (TSX: TOS). Following the release of the financial results for the 1st quarter, analyst Sara Elford reiterated her speculative buy recommendation, and one-year price target of $2.15, a 123% premium to the $0.96 price the day the report was issued.

InvestmentPitch.com has produced a "video news alert" about TSO3 based on this research report. If this link is not enabled, please visit www.InvestmentPitch.com and enter "TSO3" in the search box.

Watch the video on YouTube

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_8deul8n2/Canaccord-Genuity--Updated-Coverage--TSO3-Inc-TSX-TOS

TSO3 is an innovator in low temperature sterilization technology for medical devices in healthcare settings. The company uses ozone as its sterilant, which offers advantageous replacement solutions to other low temperature sterilization processes currently used in hospitals.

With advancement in medical techniques leading to more use of minimally invasive surgery, operating rooms are increasing their use of complex devices which cannot be sterilized through the use of heat.

The first product, the 125L, is intended for the sterilization of heat-sensitive medical instruments. The 125L+, a second generation sterilization platform, added faster cycles, loading capacity and increased compatibility.

This product has received clearance in Canada and the European Union. Following a 60-day review of the company's submission by the U.S. Regulatory Agency, the Agency recognized the uniqueness of the technology and has recommended a de novo classification pathway.

The company is also targeting initial marketing of the smaller 80L product.

Elford believes the technology platform is game changing and applicable across multiple products and end-markets, and the cash balance is sufficient to fund the recent burn rate well into 2015.

Elford commented, "The U.S. clearance is still a matter of when and not if, in our view, and we think the probability is high that TSO3 will become an acquisition target following a successful FDA outcome."

The shares are currently trading at $0.90, and with 72.9 million shares outstanding, the company is capitalized at $65.6 million.

As we stated, this $0.90 price is well below Canaccord Genuity's target price of $2.15.

For more information, please visit the company's website www.tso3.com or contact Caroline Côté, Director of Investor and Business Relations at 418-651-0003 ext 237 or email ccote@tso3.com.

For more information about Canaccord Genuity or to obtain a copy of their research report, contact your nearest Canaccord Genuity office. Their branches are listed on their website at www.canaccord.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing three minute videos based on news releases and research reports.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com

copyright (c) newsfile corp. 2012. all rights reserved

TSO3 Inc on 6ix

Story so far

Earlier from TSO3

Later from TSO3

All TSO3 news releases